Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region

Description

Global Cholangiocarcinoma market is estimated to be valued at US$ 423.2 Mn in 2023 and is expected to reach US$ 1,600.7 Mn by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 20.9% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 423.2 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	20.90%	2030 Value Projection:	US$ 1,600.7 Mn

Figure 1. Global Cholangiocarcinoma Market Share (%), By Therapy Type, 2023

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that originates in the bile ducts. Cholangiocarcinoma is a relatively rare cancer which needs to be diagnosed at an advanced stage because the symptoms of the cancer often appears late until the disease is at its well-advanced stage. The exact cause of cholangiocarcinoma is unknown, but it is believed that factors such as chronic inflammation of the bile ducts, certain infections (e.g., with the liver fluke parasite), and certain risk factors (e.g., smoking, heavy alcohol use) may increase the risk of developing this cancer. Diagnosis typically involves a combination of imaging studies, such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), as well as tissue biopsies to confirm the presence of cancer. Treatment options for cholangiocarcinoma depends on the stage of the cancer and the patient's overall health. The treatments are surgery, radiation therapy, chemotherapy, and other targeted therapies. Prognosis for cholangiocarcinoma varies depending on the stage at which it is diagnosed, and early detection and intervention are crucial for improving outcomes.

Market Dynamics

Key players are engaged in research and development activities which is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, in February 2022, Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, a Germany-based clinical research institution, initiated a clinical trial titled "A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer". The study is currently in phase 2 which is estimated to get completed by December 2024.

Key features of the study:

This report provides an in-depth analysis of the global cholangiocarcinoma market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cholangiocarcinoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson & Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

Global Cholangiocarcinoma Market, By Cancer Type:
- Perihilar
- Distal
- Extrahepatic Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
Global Cholangiocarcinoma Market, By Therapy Type:
- Targeted Drug Therapy
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- 5-fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Novartis AG
- LES LABORATOIRES SERVIER
- F. Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.

Product Code: CMI4435

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Cancer Type
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Product Launches/Approvals
Recent Trends
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Cholangiocarcinoma Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Cholangiocarcinoma Market, By Cancer Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Extrahepatic Cholangiocarcinoma
Perihilar
Distal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Intrahepatic Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Cholangiocarcinoma Market, By Therapy Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Targeted Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Pemigatinib
Ivosidenib
Futibatinib
Infigratinib
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
5- fluorouracil
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Pembrolizumab
Others (Late phase pipeline drugs)
Others (Pain Medications and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

7. Global Cholangiocarcinoma Market, By Route of Administration, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Oral
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Subcutaneous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Intravenous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends

8. Global Cholangiocarcinoma Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

9. Global Cholangiocarcinoma Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and By Y-o-Y Growth, By Region, 2018 - 2030, (US$ Mn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- BridgeBio Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
Analysts' Views

11. Section

References
Research Methodology
About us and Sales Contact